A Case Report of Alloimmune Hepatitis after Direct-acting Antiviral Treatment in a Liver Transplant Patient
Open Access
- 10 October 2020
- journal article
- research article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 8 (4), 1-4
- https://doi.org/10.14218/jcth.2020.00062
Abstract
Direct-acting antiviral (DAA) therapy is often well-tolerated, and adverse events from DAA therapy are uncommon. We report a case of a woman who underwent orthotopic liver transplant for chronic hepatitis C infection and later developed alloimmune hepatitis shortly after starting DAA therapy for recurrent hepatitis C infection. The patient developed acute alloimmune hepatitis approximately 2 weeks after starting treatment with sofosbuvir, velpatasvir, and voxilaprevir. This case report proposes a dysregulation of immune surveillance due to the DAA stimulation of host immunity and rapid elimination of hepatitis C viral load as a precipitating factor for the alloimmune process, leading to alloimmune hepatitis in a post-transplant patient who starts on DAA.Keywords
This publication has 20 references indexed in Scilit:
- “Plasma Cell Hepatitis” in Liver Allografts: Identification and Characterization of an IgG4-Rich CohortAmerican Journal of Transplantation, 2013
- Autoimmune Hepatitis After Liver TransplantationClinical Gastroenterology and Hepatology, 2012
- De Novo Autoimmune Hepatitis after Liver TransplantationSeminars in Liver Disease, 2011
- Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipientsJournal of Hepatology, 2010
- Current views on rejection pathology in liver transplantationTransplant International, 2010
- Distinct Roles for CCR4 and CXCR3 in the Recruitment and Positioning of Regulatory T Cells in the Inflamed Human LiverThe Journal of Immunology, 2010
- Pegylated interferon–induced immune-mediated hepatitis post–liver transplantationLiver Transplantation, 2006
- Effect of CD4+CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitisJournal of Autoimmunity, 2005
- Rapamycin Successfully Treats Post-Transplant Autoimmune HepatitisAmerican Journal of Transplantation, 2005
- Impairment of CD4+CD25+ regulatory T-cells in autoimmune liver diseaseJournal of Hepatology, 2004